Statin therapy and increased coronary heart disease risk in primary prevention of people with enhanced low-grade inflammation

Basit Öğe Kaydı
dc.contributor.authorOnat A.
dc.contributor.authorAydin M.
dc.contributor.authorKöro?lu B.
dc.contributor.authorCan G.
dc.contributor.authorKaya H.
dc.contributor.authorAdemo?lu E.
dc.date.accessioned2024-04-24T18:46:06Z
dc.date.available2024-04-24T18:46:06Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: We investigated whether statin treatment, associated with slightly increased risk of incident diabetes, confers elevated coronary heart disease (CHD) risk, and circumstances thereof.Material and Methods: Totally, 2959 participants 270 of whom were medicated with statins, and free of CHD at baseline, were analyzed at 7.9-years' follow-up using Cox regression.Results: Participants using statin at baseline-compared with remaining participants-had significantly higher values of metabolic syndrome (MetS) components, but lower apolipoprotein B, were fewer current smokers, and had similar HDL- and LDL-cholesterol levels. Women additionally had higher plasma fibrinogen and lipoprotein[Lp](a). Adjusted Lp(a) concentrations were significantly associated with statin medication, especially in men. In Kaplan-Meier analyses for 381 incident CHD cases (stratified to gender, age category and changed status of statin usage) demonstrated steadily separating curves in statin users, compared with non-users (Log rank <0.0001). Cox regression hazard ratio for developing incident CHD was 2.42 (95% CI 1.80; 3.25) in individuals using statin, after adjustment for traditional risk factors, in men irrespective of MetS-status.Conclusion: Appropriately instituted statin therapy in population subsets with MetS or enhanced inflammation may increase CHD risk in a primary prevention setting. Excess risk imparting may be attributed to a modifying effect of statins on Lp(a). Copyright © 2014 by Türkiye Klinik leri.en_US
dc.identifier.endpage127en_US
dc.identifier.issn1306-7656
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-84919381173
dc.identifier.scopusqualityQ4
dc.identifier.startpage118en_US
dc.identifier.urihttps://hdl.handle.net/11468/25057
dc.identifier.volume26en_US
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherOrtadogŸu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S.en_US
dc.relation.ispartofTurkiye Klinikleri Cardiovascular Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutoimmunityen_US
dc.subjectCoronary Diseaseen_US
dc.subjectHydroxymethylglutaryl-Coa Reductase İnhibitorsen_US
dc.subjectLipoprotein(A)en_US
dc.subjectPrimary Preventionen_US
dc.titleStatin therapy and increased coronary heart disease risk in primary prevention of people with enhanced low-grade inflammationen_US
dc.titleStatin therapy and increased coronary heart disease risk in primary prevention of people with enhanced low-grade inflammation
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu